Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2025, with a specific report date of September 18, 2025. The filing serves to disclose a significant corporate development regarding the Company's intellectual property portfolio rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent covering the Company's next-generation XSense™ Cryoprobes. This development strengthens the Company's intellectual property protection for its core technology.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the accompanying press release (Exhibit 99.1). No specific financial guidance, quantitative outlook, or new risk factors are detailed within the body of this Form 6-K text. The filing notes that the press release is incorporated into the Company's existing Registration Statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the specific claims and scope of the granted U.S. patent for XSense™ Cryoprobes by reviewing Exhibit 99.1.
- Confirm the status of the patent application and any remaining conditions for issuance.
- Review the "Forward Looking Statements" in the press release for potential risks related to commercialization or regulatory approval.
- Check subsequent filings for any financial impact or strategic shifts resulting from this patent allowance.